Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed Kaposi's sarcoma (KS)~* HIV positive~* Evaluable disease involving the skin and/or viscera~  * At least 5 lesions not previously treated with local therapy if restricted to the skin~ * Pulmonary lesions evaluable by CT scan~ * Gastrointestinal lesions evaluable by visualization or fiberoptic instrumentation~* Presence of at least one of the following indications for cytotoxic chemotherapy:~  * Pulmonary involvement~ * Visceral involvement~ * Pain~ * Edema~ * Ulcerating lesions~ * Decreased range of joint motion due to KS~ * Multiple lesions not amenable to local therapy~ * Lymphedema that impairs mobility or range of motion~ * Significant psychological impact leading to social withdrawal~* Progressive disease within the past 3 weeks while receiving a stable regimen of highly active antiretroviral therapy for at least 4 weeks unless there is a need for urgent chemotherapy~* Prior participation on this study allowed, provided patient was removed from study due to non-pancreatic hyperamylasemia and the following are true:~  * No dose-limiting toxicity by clinical and laboratory assessment~ * Pancreatic amylase portion normal by fractionated amylase~ * Lipase normal~ * No symptoms referable to the pancreas~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 30-100%~Life expectancy:~* More than 2 months~Hematopoietic:~* Hemoglobin at least 9.0 g/dL~* Absolute neutrophil count at least 750/mm\^3~* Platelet count at least 75,000/mm\^3~Hepatic:~* Bilirubin no greater than 3.8 mg/dL with direct fraction no greater than 0.3 mg/dL and indirect fraction no greater than 3.5 mg/dL if due to protease inhibitor therapy~* PT or aPTT no greater than 120% of control unless due to lupus-type anticoagulant~* AST no greater than 2.5 times upper limit of normal~* No prior hepatic cirrhosis~* No hepatic dysfunction~Renal:~* Creatinine no greater than 1.5 mg/dL~* Creatinine clearance at least 60 mL/min~Cardiovascular:~* No congestive heart failure~* Ejection fraction at least 40% by MUGA or echocardiogram~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception during and for 2 months after study participation~* No clinically significant autoimmune disease~* No active, gross gastrointestinal bleeding or uncontrolled peptic ulcer disease~* No prior inflammatory bowel disease~* No other prior or concurrent malignancy except squamous cell carcinoma in situ of the cervix or anus, completely resected basal cell carcinoma, or malignancy in complete remission for at least 1 year from the time a response was first documented~* No severe or life-threatening infection within the past 2 weeks~* No abnormality that would be scored as grade 3 toxicity except lymphopenia or direct manifestations of KS~* No known hypersensitivity to interleukin-12 (IL-12) or other compounds known to cross-react with IL-12~* No other medical condition that would preclude study entry~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* More than 2 weeks since prior cytokines or colony-stimulating factors other than epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF)~* No prior combination interleukin-12 and doxorubicin HCl liposome except for patients previously treated on this protocol who are being enrolled for paclitaxel salvage therapy~* No concurrent immunomodulatory agents~* No concurrent cytokines except epoetin alfa or G-CSF~Chemotherapy:~* See Disease Characteristics~* See Biologic therapy~* At least 3 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas)~* More 6 months since prior suramin~* No other concurrent cytotoxic chemotherapy~Endocrine therapy:~* More than 2 months since prior systemic glucocorticoid steroids at doses sufficient to affect immune response (e.g., more than 20 mg of prednisone for more than 1 week)~* Concurrent replacement glucocorticoid therapy allowed~* No other concurrent systemic glucocorticoid therapy~Radiotherapy:~* Not specified~Surgery:~* Not specified~Other:~* Concurrent antiretroviral therapy required~* No other concurrent anti-KS therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete